JP2014531456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531456A5 JP2014531456A5 JP2014532068A JP2014532068A JP2014531456A5 JP 2014531456 A5 JP2014531456 A5 JP 2014531456A5 JP 2014532068 A JP2014532068 A JP 2014532068A JP 2014532068 A JP2014532068 A JP 2014532068A JP 2014531456 A5 JP2014531456 A5 JP 2014531456A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- poly
- composition according
- docetaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002105 nanoparticle Substances 0.000 claims 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 6
- 229960003668 docetaxel Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 206010070308 Refractory cancer Diseases 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 4
- -1 (lactic acid) -poly (ethylene) Chemical class 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 229920000359 diblock copolymer Polymers 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229920002959 polymer blend Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229920000547 conjugated polymer Polymers 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161537980P | 2011-09-22 | 2011-09-22 | |
| US61/537,980 | 2011-09-22 | ||
| PCT/US2012/056891 WO2013044219A1 (en) | 2011-09-22 | 2012-09-24 | Methods of treating cancers with therapeutic nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014531456A JP2014531456A (ja) | 2014-11-27 |
| JP2014531456A5 true JP2014531456A5 (enExample) | 2015-11-12 |
Family
ID=47049354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532068A Pending JP2014531456A (ja) | 2011-09-22 | 2012-09-24 | 治療用ナノ粒子と癌を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150017245A1 (enExample) |
| EP (1) | EP2747761A1 (enExample) |
| JP (1) | JP2014531456A (enExample) |
| WO (1) | WO2013044219A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010005725A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| EP2309990B2 (en) | 2008-06-16 | 2017-03-15 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| WO2011084513A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
| PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PT2895156T (pt) | 2012-09-17 | 2019-06-28 | Pfizer | Processo para a preparação de nanopartículas terapêuticas |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112015032758A2 (pt) * | 2013-06-28 | 2017-07-25 | Bind Therapeutics Inc | nanopartículas poliméricas de docetaxel para o tratamento de câncer |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3311845B1 (en) | 2013-09-16 | 2020-01-15 | Astrazeneca AB | Therapeutic polymeric nanoparticles and methods of making and using same |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| JP6348616B2 (ja) | 2014-03-14 | 2018-06-27 | ファイザー・インク | 治療剤を含む治療用ナノ粒子ならびにその製造および使用方法 |
| ES2872552T3 (es) | 2014-03-17 | 2021-11-02 | Merck Sharp & Dohme | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas |
| EP3131542A1 (en) * | 2014-04-18 | 2017-02-22 | Pfizer Inc. | Methods of treating cancers with therapeutic nanoparticles |
| CA2946155A1 (en) * | 2014-04-18 | 2015-10-22 | Pfizer Inc. | Nanoparticles comprising docetaxel for treating cancers having a k-ras mutation |
| US10080720B2 (en) * | 2014-07-15 | 2018-09-25 | Gainia (Shanghai) Patent Technology Ltd. | Pharmaceutical composition containing docetaxel |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| US11304898B2 (en) | 2015-06-09 | 2022-04-19 | Sun Pharma Advanced Research Company Ltd | Method of treating carcinoma |
| PE20181531A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacuna del virus herpes simple |
| EP3365007A4 (en) | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | WIDE SPECTRUM VACCINE AGAINST INFLUENZA VIRUS |
| TW201729838A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
| MA46317A (fr) | 2015-10-22 | 2019-08-07 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| PT3718565T (pt) | 2015-10-22 | 2022-07-20 | Modernatx Inc | Vacinas contra vírus respiratórios |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| SMT202200310T1 (it) | 2015-12-23 | 2022-09-14 | Modernatx Inc | Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40 |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| WO2019004338A1 (ja) * | 2017-06-28 | 2019-01-03 | 株式会社 先端医療開発 | 医薬組成物及び腫瘍免疫活性促進剤 |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776100T3 (es) * | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
| EP2136788B1 (en) * | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| WO2010005725A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| EP2309990B2 (en) * | 2008-06-16 | 2017-03-15 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| JP2010106019A (ja) * | 2008-10-02 | 2010-05-13 | Kanazawa Univ | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 |
| US8357401B2 (en) * | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| EA201290497A1 (ru) * | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
| WO2011084513A2 (en) * | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| CN102740895B (zh) * | 2009-12-23 | 2016-02-24 | 伊利诺伊大学董事会 | 纳米轭合物以及纳米轭合物配制品 |
-
2012
- 2012-09-24 WO PCT/US2012/056891 patent/WO2013044219A1/en not_active Ceased
- 2012-09-24 US US14/346,456 patent/US20150017245A1/en not_active Abandoned
- 2012-09-24 JP JP2014532068A patent/JP2014531456A/ja active Pending
- 2012-09-24 EP EP12775568.4A patent/EP2747761A1/en not_active Withdrawn
-
2017
- 2017-05-23 US US15/603,151 patent/US20170266293A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531456A5 (enExample) | ||
| Lee et al. | PLA micro-and nano-particles | |
| JP2019512006A5 (enExample) | ||
| Perinelli et al. | PEGylated polylactide (PLA) and poly (lactic-co-glycolic acid)(PLGA) copolymers for the design of drug delivery systems | |
| HRP20200407T1 (hr) | Terapeutske polimerne nanočestice i postupci dobivanja i korištenja istih | |
| Cheng et al. | Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery | |
| JP2013527232A5 (enExample) | ||
| Yu et al. | Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) complex nanoparticles for tumor therapy | |
| JP2017508803A5 (enExample) | ||
| Aguilar et al. | On-demand drug release and hyperthermia therapy applications of thermoresponsive poly-(NIPAAm-co-HMAAm)/polyurethane core-shell nanofiber mat on non-vascular nitinol stents | |
| JP2013503174A5 (enExample) | ||
| JP2010513526A5 (enExample) | ||
| EA201170039A1 (ru) | Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения | |
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| CN105327353B (zh) | 一种模拟超氧化物歧化酶/过氧化氢酶的纳米药物、制备方法及其应用 | |
| JP2015134825A5 (enExample) | ||
| US20150366975A1 (en) | Thermosensitive injectable hydrogel for drug delivery | |
| NZ708506A (en) | Methods of treating bladder cancer | |
| RU2019133284A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| JP2019521180A5 (enExample) | ||
| CN103877029B (zh) | 一种磁性载5-氟尿嘧啶聚乳酸羟基乙酸共聚物材料的制备方法 | |
| JP2015512398A5 (enExample) | ||
| JP2017505800A5 (enExample) | ||
| Hong et al. | Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine | |
| WO2013089394A2 (ko) | 고분자 나노입자 수용액 조성물 및 그 제조방법 |